These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 24157993)

  • 1. Point-of-care testing governance in New Zealand: a national framework.
    Musaad SM; Herd G
    N Z Med J; 2013 Sep; 126(1383):72-9. PubMed ID: 24157993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical governance and point-of-care testing at health provider level.
    Herd G; Musaad SM
    N Z Med J; 2015 Jul; 128(1417):41-6. PubMed ID: 26149903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical governance: implications for point-of-care testing.
    Freedman DB
    Ann Clin Biochem; 2002 Sep; 39(Pt 5):421-3. PubMed ID: 12227847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Point-of-care testing governance in New Zealand through the lens of quality: an update on a national regulatory framework.
    Musaad SM; Herd GC
    N Z Med J; 2019 Jul; 132(1499):56-63. PubMed ID: 31352475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of a training program for device operators in the Australian Government's Point of Care Testing in General Practice Trial: issues and implications for rural and remote practices.
    Shephard MD; Mazzachi BC; Watkinson L; Shephard AK; Laurence C; Gialamas A; Bubner T
    Rural Remote Health; 2009; 9(3):1189. PubMed ID: 19689171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Point-of-care testing. Conception, regulations, and usage.
    Cvitkovic M
    Crit Care Nurs Q; 2011; 34(2):116-27. PubMed ID: 21407006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality in point-of-care testing.
    Nichols JH
    Expert Rev Mol Diagn; 2003 Sep; 3(5):563-72. PubMed ID: 14510177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality improvement in New Zealand healthcare. Part 7: clinical governance--an attempt to bring quality into reality.
    Perkins R; Pelkowitz A; Seddon M;
    N Z Med J; 2006 Oct; 119(1243):U2259. PubMed ID: 17063199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical governance development: learning from the New Zealand experience.
    Gauld R
    Postgrad Med J; 2014 Jan; 90(1059):43-7. PubMed ID: 24198340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assuring quality in point-of-care testing: evolution of technologies, informatics, and program management.
    Lewandrowski K; Gregory K; Macmillan D
    Arch Pathol Lab Med; 2011 Nov; 135(11):1405-14. PubMed ID: 22032566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Point-of-care-testing and Clinical Governance.
    Pearson J
    Clin Chem Lab Med; 2006; 44(6):765-7. PubMed ID: 16729866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of an Aboriginal community-based renal disease management program incorporating point of care testing for urine albumin:creatinine ratio.
    Shephard MD; Allen GG; Paizis K; Barbara JA; Batterham M; Vanajek A
    Rural Remote Health; 2006; 6(4):591. PubMed ID: 17022724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Executive summary. The National Academy of Clinical Biochemistry Laboratory Medicine Practice Guideline: evidence-based practice for point-of-care testing.
    Nichols JH; Christenson RH; Clarke W; Gronowski A; Hammett-Stabler CA; Jacobs E; Kazmierczak S; Lewandrowski K; Price C; Sacks DB; Sautter RL; Shipp G; Sokoll L; Watson ID; Winter W; Zucker ML;
    Clin Chim Acta; 2007 Apr; 379(1-2):14-28; discussion 29-30. PubMed ID: 17270169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the role and value of a national office to coordinate Liverpool Care Pathway implementation in New Zealand.
    Mackenzie T; Innes J; Boyd M; Keane B; Boxall J; Allan S
    Int J Evid Based Healthc; 2011 Sep; 9(3):252-60. PubMed ID: 21884453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. National healthcare systems and the need for health information governance.
    Hovenga EJ
    Stud Health Technol Inform; 2013; 193():3-23. PubMed ID: 24018509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementation of an expanded point-of-care testing (POCT) site inspection checklist in a large academic medical center: implications for the management of a POCT program.
    Gregory K; Tse JY; Wu R; Lewandrowski K
    Clin Chim Acta; 2012 Dec; 414():27-33. PubMed ID: 22902708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of the Therapeutic Goods Administration and the Medicine and Medical Devices Safety Authority in evaluating complementary and alternative medicines in Australia and New Zealand.
    Ghosh D; Skinner M; Ferguson LR
    Toxicology; 2006 Apr; 221(1):88-94. PubMed ID: 16481089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does POCT reduce the risk of error in laboratory testing?
    Plebani M
    Clin Chim Acta; 2009 Jun; 404(1):59-64. PubMed ID: 19298804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of a point-of-care testing program.
    Gregory K; Lewandrowski K
    Clin Lab Med; 2009 Sep; 29(3):433-48. PubMed ID: 19840678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.